Evidence map›Paper›PMID 42151759›Full record

ReviewCellular & molecular biology letters2026

Genomic context of mutations in MIR142 in blood cancers: summary and integrative analysis.

Wladyslaw Wegorek, Adrian Tire, Daniel Kuznicki, Julia Richter, Maciej Giefing, Wolfram Klapper, Piotr Kozlowski, Paulina Galka-Marciniak

Abstract readReview
In one paragraph

Review in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wladyslaw Wegorek *Department of Molecular Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Adrian Tire *Department of Molecular Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Daniel KuznickiDepartment of Molecular Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Julia RichterHematopathology Section, Department of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany.
Maciej GiefingInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Wolfram KlapperHematopathology Section, Department of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany.
Piotr KozlowskiDepartment of Molecular Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland. kozlowp@ibch.poznan.pl.
Paulina Galka-MarciniakDepartment of Molecular Genetics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland. pgalka@ibch.poznan.pl.

Funding

the National Science Centre Poland 2020/39/B/NZ2/01004the National Science Centre Poland 2020/39/B/NZ5/01970the National Science Centre Poland 2020/39/D/NZ2/03106
6 · The paper itself

Abstract

MIR142 is the most frequently mutated microRNA (miRNA) gene in cancer, with recurrent alterations observed particularly in hematologic malignancies of lymphoid origin. It is expressed at very high levels in blood cells and plays an essential role in the development, differentiation, and maturation of various lymphopoietic and hematopoietic lineages. To gain a deeper understanding of MIR142 mutations, we summarize all data on these mutations, including their frequency in different cancers, their location within the miR-142 precursor, and their functional consequences. We also analyzed MIR142 mutations within a broader genomic context in thousands of cancers, including hundreds of blood neoplasms. Our results show that the most prevalent mutations in the MIR142 gene originate from a clearly distinct hotspot in hematologic malignancies, concentrated mainly within the sequence of the secondary miR-142 precursor. We found substantial differences in mutation frequency and distribution across cancer types. This indicates that MIR142 alterations are not random consequences of an increased mutational load but are likely subject to positive selection, underscoring their biological and clinical significance.

Indexed as

Hematologic NeoplasmsMicroRNAsMutationHumansMicroRNAsMIR142, humanAMLCLLDLBCLLymphomamiR-142miRNA mutations

Identifiers

PMID42151759
PMCPMC13435480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.